Literature DB >> 20470805

Early developmental alterations in GABAergic protein expression in fragile X knockout mice.

Daniel C Adusei1, Laura K K Pacey, Duke Chen, David R Hampson.   

Abstract

Fragile X syndrome is the most common heritable form of mental retardation. It is caused by silencing of the Fmr1 gene and the absence of the encoded protein. The purpose of this study was to examine global protein expression levels of GABA(A) and GABA(B) receptors, and GABAergic enzymes and trafficking proteins in fragile X knockout mice during brain maturation. Quantitative western blotting of homogenates of forebrain revealed that the levels of GABA(A) beta1 and beta3, GABA(B)-R1, NKCC1, KCC2, gephyrin and ubiquilin were not significantly different from wild-type mice at any of the postnatal time points examined. In contrast, the GABA(A) receptor alpha1, beta2, and delta subunits, and the GABA enzymes GABA transaminase and succinic semialdehyde dehydrogenase were down-regulated during postnatal development, while GAD65 was up-regulated in the adult knockout mouse brain. The GABA(A) receptor alpha1 and beta2 subunits displayed a divergent pattern of developmental expression whereby alpha1 was reduced in the immature brain but regained a level of expression similar to wild-type mice by adulthood, while the expression of beta2 was similar to wild-types at postnatal day 5 but reduced at day 12 and in the adult brain. The GABA(A) receptor delta subunit and the GABA catabolic enzymes GABA transaminase and succinic semialdehyde dehydrogenase were simultaneously but transiently decreased only at postnatal day 12. Our results demonstrate that GABA(A) receptor subunits and GABA enzymes display complex patterns of changes during brain development suggesting that dynamic interactions may occur between GABA transmitter levels and GABA receptors in fragile X syndrome. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470805     DOI: 10.1016/j.neuropharm.2010.05.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  67 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

Review 3.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome.

Authors:  Lawrence K Fung; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2015-12-18       Impact factor: 13.382

5.  Translational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cells.

Authors:  Se Jin Jeon; Ji-Woon Kim; Ki Chan Kim; So Min Han; Hyo Sang Go; Jung Eun Seo; Chang Soon Choi; Jong Hoon Ryu; Chan Young Shin; Mi-Ryoung Song
Journal:  Cell Mol Neurobiol       Date:  2013-12-12       Impact factor: 5.046

Review 6.  GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Res       Date:  2014-11-26       Impact factor: 4.939

7.  The effects of prenatal H1N1 infection at E16 on FMRP, glutamate, GABA, and reelin signaling systems in developing murine cerebellum.

Authors:  S Hossein Fatemi; Timothy D Folsom; Stephanie B Liesch; Rachel E Kneeland; Mahtab Karkhane Yousefi; Paul D Thuras
Journal:  J Neurosci Res       Date:  2016-10-13       Impact factor: 4.164

8.  The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.

Authors:  Paola Sgadò; Mark Dunleavy; Sacha Genovesi; Giovanni Provenzano; Yuri Bozzi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-09

9.  Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala.

Authors:  Brandon S Martin; Joshua G Corbin; Molly M Huntsman
Journal:  J Neurophysiol       Date:  2014-05-21       Impact factor: 2.714

Review 10.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.